Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. Show more
Location: Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States | Website: https://larimartx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
372.3M
52 Wk Range
$1.61 - $9.50
Previous Close
$4.35
Open
$4.40
Volume
1,886,393
Day Range
$4.18 - $4.46
Enterprise Value
232.4M
Cash
138.5M
Avg Qtr Burn
-23.07M
Insider Ownership
1.07%
Institutional Own.
83.52%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia | BLA Submission |